ADVFN Logo ADVFN
市場データ
ニュース
投資ツール
市場
発見

Hot Features

Follow Feed

フォローフィードコミュニティでトレーダーや投資家とつながりましょう.

ライブオプションフロー

包括的なオプション データを調査し、オプション フローで高度なフィルターを使用します.

モニター

ターミナル モニターで株式と資産のウォッチリストを整理および監視します
サインイン Premium Iconプレミアム Help Menu
Bitcoin
92,551.81
0.63%
S&P 500
6,021.63
0.57%
Dow Jones
44,860.31
0.28%
US Dollar vs Yen
152.2915
-0.47%
Brent Oil
72.335
-0.16%
Registration Strip Icon for charts 登録してリアルタイムのチャート、分析ツール、価格を入手してください。
登録
  1. ホーム
  2. 投資
  3. 株式
  4. アメリカ
  5. NASDAQ
  6. Virios Therapeutics Inc (VIRI)

  7. Virios Therapeutics Inc (VIRI) ニュース

VIRI

Virios Therapeutics (VIRI)

Virios Therapeutics Inc
から:
次の項目別のソート:
 Showing the most relevant articles for your search:NASDAQ:VIRI
日付受信時刻ニュースソース見出しコード企業名
2024/11/2123 : 15Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:VIRIVirios Therapeutics Inc
2024/11/0822 : 15Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:VIRIVirios Therapeutics Inc
2024/11/0721 : 15Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:VIRIVirios Therapeutics Inc
2024/10/3022 : 25Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:VIRIVirios Therapeutics Inc
2024/10/1805 : 30Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:VIRIVirios Therapeutics Inc
2024/10/1805 : 29Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:VIRIVirios Therapeutics Inc
2024/10/1605 : 19Edgar (US Regulatory)Form SC 13D - General Statement of Acquisition of Beneficial OwnershipNASDAQ:VIRIVirios Therapeutics Inc
2024/10/0721 : 06Edgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:VIRIVirios Therapeutics Inc
2024/10/0721 : 02Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:VIRIVirios Therapeutics Inc
2024/10/0720 : 05GlobeNewswire Inc.Virios Therapeutics, Inc. and Wex Pharmaceuticals, Inc. Announce Business Combination to Form Dogwood Therapeutics, Inc. (Nasdaq: “DWTX”)NASDAQ:VIRIVirios Therapeutics Inc
2024/08/0923 : 15Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:VIRIVirios Therapeutics Inc
2024/08/0822 : 30Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:VIRIVirios Therapeutics Inc
2024/08/0822 : 15GlobeNewswire Inc.Virios Therapeutics Announces Second Quarter 2024 Financial ResultsNASDAQ:VIRIVirios Therapeutics Inc
2024/08/0122 : 41GlobeNewswire Inc.Virios Therapeutics to Report Second Quarter 2024 Financial Results on Thursday, August 8, 2024NASDAQ:VIRIVirios Therapeutics Inc
2024/07/2322 : 15GlobeNewswire Inc.Virios Therapeutics Announces Completion of Enrollment in IMC-2 Phase 2 Long-COVID Study Being Conducted by Bateman Horne CenterNASDAQ:VIRIVirios Therapeutics Inc
2024/06/2022 : 15Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:VIRIVirios Therapeutics Inc
2024/06/1222 : 15Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:VIRIVirios Therapeutics Inc
2024/05/2302 : 30GlobeNewswire Inc.Virios Therapeutics Announces Closing of $1.7 Million Public Offering of Common Stock to Commence Preparations for Planned IMC-2 Long-COVID Phase 2b StudyNASDAQ:VIRIVirios Therapeutics Inc
2024/05/2105 : 05Edgar (US Regulatory)Form 424B4 - Prospectus [Rule 424(b)(4)]NASDAQ:VIRIVirios Therapeutics Inc
2024/05/2022 : 28Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:VIRIVirios Therapeutics Inc
2024/05/2009 : 53GlobeNewswire Inc.Virios Therapeutics Announces Pricing of $1.7 Million Public Offering of Common Stock to Commence Preparations for Planned IMC-2 Long-COVID Phase 2b StudyNASDAQ:VIRIVirios Therapeutics Inc
2024/05/1805 : 10GlobeNewswire Inc.Virios Therapeutics Announces Proposed Public Offering of Common Stock to Commence Preparations for Planned IMC-2 Long-COVID Phase 2b StudyNASDAQ:VIRIVirios Therapeutics Inc
2024/05/1805 : 01Edgar (US Regulatory)Form 424B4 - Prospectus [Rule 424(b)(4)]NASDAQ:VIRIVirios Therapeutics Inc
2024/05/1023 : 30Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:VIRIVirios Therapeutics Inc
2024/05/0921 : 01Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:VIRIVirios Therapeutics Inc
2024/05/0920 : 45GlobeNewswire Inc.Virios Therapeutics Announces First Quarter 2024 Financial Results and Provides Corporate UpdateNASDAQ:VIRIVirios Therapeutics Inc
2024/05/0806 : 25Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:VIRIVirios Therapeutics Inc
2024/05/0222 : 15GlobeNewswire Inc.Virios Therapeutics to Report First Quarter 2024 Financial Results on Thursday, May 9, 2024NASDAQ:VIRIVirios Therapeutics Inc
2024/03/2622 : 15GlobeNewswire Inc.Virios Therapeutics Announces Publication of International Patent for IMC-2 Covering Antiviral Treatment of Long-COVIDNASDAQ:VIRIVirios Therapeutics Inc
2024/03/0907 : 00Edgar (US Regulatory)Form 10-K/A - Annual report [Section 13 and 15(d), not S-K Item 405]: [Amend]NASDAQ:VIRIVirios Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:VIRI

最近閲覧した銘柄

PM
XAUUSD
Gold vs US Dollar
CCOM
SILVER
SILVER
COIN
ADAUSD
Cardano
NYSE
MCD
McDonalds
AMEX
XLE
Energy Select Sector SPDR
FX
USDGBP
US Dollar vs Sterling
NYSE
MRK
Merck
NYSE
NKE
Nike
AMEX
XLV
Health Care Select Sector
NYSE
JPM
JP Morgan Chase
CCOM
US500
US 500
NASDAQ
GOOGL
Alphabet
NASDAQ
AAPL
Apple
CCOM
US100
US Tech 100
NYSE
VZ
Verizon Communications
NYSE
KO
Coca Cola
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

日本
会社情報
ビジネス
人気
アプリを入手
App Store
Google Play

顧客サポート: +44 (0) 203 8794 460 | support@advfn.com

ADVFNのサービスをご利用いただくには、利用規約

© 2024 ADVFN PLC - 全著作権所有

BLACK FRIDAY

ADVFN

25周年を記念 1999-2024

Forexで最大60%オフ

1年間40％、2年間40％、*3年間60％

*3年間で¥ 153396、たったの¥ 61358